FB 301

Phase 2Small molecule

FFreya Biosciences ApS

FB 301 is one of 2 small molecule programs targeting Bacterial Vaginosis (BV). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial Vaginosis (BV)Recruiting

Vaginal DysbiosisRecruiting

Bacterial Vaginosis (BV)Phase 2

Recruiting

Vaginal DysbiosisPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Bacterial Vaginosis (BV)

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Phase 2

1 2

FB 301

FFreya Biosciences ApS

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Bacterial Vaginosis (BV)

NCT07481955

Q3 2027

Phase 2Recruiting

Vaginal Dysbiosis

NCT07453069

Clinical

Trials by Indication[1]

Vaginal Dysbiosis1 trial

A Randomized, Double-blind, Three Arm, Multi-center Phase 2 Study to Investigate the Molecular Efficacy and Safety of FB301/Chlorhexidine Compared With FB301/Sham and Placebo/Sham in a Mock FET Cycle in Female Participants 18-40 Years of Age With Asymptomatic Vaginal Molecular Dysbiosis Planning to Undergo a Frozen Embryo Transfer (FET) Cycle

Recruiting·FFreya Biosciences ApS·Phase 2·NCT07453069·30 enrolled

Bacterial Vaginosis (BV)1 trial

Open-label Safety and Efficacy Trial of Chlorhexidine and/or Metronidazole Pre-treatment Followed by FB301 in Women With Bacterial Vaginosis

Recruiting·FFreya Biosciences ApS·Phase 2·NCT07481955·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FB 301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FB 301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FB 301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Freya Biosciences ApS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFreya Biosciences ApS

FB 301

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Vaginal Dysbiosis1 trial

Bacterial Vaginosis (BV)1 trial

References

Drug Info

Quick Facts

Related News